274 related articles for article (PubMed ID: 17657490)
1. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells.
Rudolf D; Silberzahn T; Walter S; Maurer D; Engelhard J; Wernet D; Bühring HJ; Jung G; Kwon BS; Rammensee HG; Stevanović S
Cancer Immunol Immunother; 2008 Feb; 57(2):175-83. PubMed ID: 17657490
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
3. Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86.
Habib-Agahi M; Jaberipour M; Phan TT; Searle PF
Iran J Immunol; 2008 Sep; 5(3):136-47. PubMed ID: 18791280
[TBL] [Abstract][Full Text] [Related]
4. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression.
Wehler TC; Karg M; Distler E; Konur A; Nonn M; Meyer RG; Huber C; Hartwig UF; Herr W
J Immunol Methods; 2008 Nov; 339(1):23-37. PubMed ID: 18760281
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB costimulation promotes human T cell adhesion to fibronectin.
Kim YJ; Mantel PL; June CH; Kim SH; Kwon BS
Cell Immunol; 1999 Feb; 192(1):13-23. PubMed ID: 10066342
[TBL] [Abstract][Full Text] [Related]
6. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
Lu X; Jiang X; Liu R; Zhao H; Liang Z
Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
[TBL] [Abstract][Full Text] [Related]
8. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.
Dumitriu IE; Baruah P; Finlayson CJ; Loftus IM; Antunes RF; Lim P; Bunce N; Kaski JC
Circ Res; 2012 Mar; 110(6):857-69. PubMed ID: 22282196
[TBL] [Abstract][Full Text] [Related]
9. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
10. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation.
van Stipdonk MJ; Lemmens EE; Schoenberger SP
Nat Immunol; 2001 May; 2(5):423-9. PubMed ID: 11323696
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
[TBL] [Abstract][Full Text] [Related]
12. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
13. HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Clin Cancer Res; 2007 Dec; 13(24):7329-34. PubMed ID: 18094414
[TBL] [Abstract][Full Text] [Related]
14. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
Habib-Agahi M; Jaberipour M; Searle PF
Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
[TBL] [Abstract][Full Text] [Related]
15. Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells.
Kim YJ; Brutkiewicz RR; Broxmeyer HE
Blood; 2002 Nov; 100(9):3253-60. PubMed ID: 12384425
[TBL] [Abstract][Full Text] [Related]
16. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
Numbenjapon T; Serrano LM; Chang WC; Forman SJ; Jensen MC; Cooper LJ
Exp Hematol; 2007 Jul; 35(7):1083-90. PubMed ID: 17588477
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.
Choi BK; Kim YH; Kang WJ; Lee SK; Kim KH; Shin SM; Yokoyama WM; Kim TY; Kwon BS
Cancer Res; 2007 Sep; 67(18):8891-9. PubMed ID: 17875731
[TBL] [Abstract][Full Text] [Related]
18. B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines.
Iezzi G; Protti MP; Rugarli C; Bellone M
Cancer Res; 1996 Jan; 56(1):11-5. PubMed ID: 8548749
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
[TBL] [Abstract][Full Text] [Related]
20. Costimulation of human CD28- T cells by 4-1BB ligand.
Bukczynski J; Wen T; Watts TH
Eur J Immunol; 2003 Feb; 33(2):446-54. PubMed ID: 12645943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
